Biomarkers in NSCLC: a pathologist's insight into PD-L1 and TMB (2019)

First Author: Haragan A

Attributed to: Immune-checkpoint therapy in non-small cell lung carcinoma:molecular characterisation of tumour microenvironment to improve anti-PD1/PD-L1 drug class. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Publication URI: https://www.vjoncology.com/video/stfiqkdt8dc-biomarkers-in-nsclc-a-pathologists-insight-into-pd-l1-and-tmb/

Type: Other